Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 2, 2012, Pages 316-324

  Huang, Liyue ^a   Be, Xuhai ^a   Tchaparian, Eskouhie H ^a   Colletti, Adria E ^a   Roberts, Jonathan ^a   Langley, Meghan ^a   Ling, Yun ^a   Wong, Bradley K ^a   Jin, Lixia ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 METHOXY 2 [(2 METHYL 1,3 BENZOTHIAZOL 6 YL)AMINO] 4 PYRIDINYL] 1,5,6,7 TETRAHYDRO 4H PYRROLO[3,2 C]PYRIDIN 4 ONE; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DIGOXIN; DRUG METABOLIZING ENZYME; NITROFURANTOIN; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ABCG2 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG EXCRETION; DRUG PENETRATION; DRUG SOLUBILITY; GENE; GENE DELETION; GENE EXPRESSION; GENE TARGETING; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ALGORITHMS; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BILE DUCTS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIGOXIN; FEMALE; GENE DELETION; GENE EXPRESSION; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; NITROFURANTOIN; P-GLYCOPROTEIN; PHARMACOKINETICS; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RNA; SULFASALAZINE;

EID: 84867597497     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.197046     Document Type: Article

References (44)

1. Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Humphreys JE, Lou Y, et al. (2010) Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. J Pharm Sci 99:1046-1062.
2. Adkison KK, Vaidya SS, Lee DY, Koo SH, Li L, Mehta AA, Gross AS, Polli JW, Lou Y, and Lee EJ (2008) The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. Br J Clin Pharmacol 66:233-239.
3. Anderson MD, Bandiera SM, Chang TK, and Bellward GD (1998) Effect of androgen administration during puberty on hepatic CYP2C11, CYP3A, and CYP2A1 expression in adult female rats. Drug Metab Dispos 26:1031-1038. (Pubitemid 28478266)
4. Benet LZ, Broccatelli F, and Oprea TI (2011) BDDCS applied to over 900 drugs. AAPS J 13:519-547.
5. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, et al. (2006) Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36:963-988. (Pubitemid 44844110)
6. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, et al. (2006) Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98:1739-1742. (Pubitemid 44942712)
7. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
8. Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, and Bates SE (2006) Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 235:84-92.
9. Furukawa T, Wakabayashi K, Tamura A, Nakagawa H, Morishima Y, Osawa Y, and Ishikawa T (2009) Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations. Pharm Res 26:469-479.
10. Gry M, Rimini R, Strömberg S, Asplund A, Pontén F, Uhlén M, and Nilsson P (2009) Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 10:365-379.
11. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, and Sugiyama Y (2005) Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807. (Pubitemid 41206035)
12. Hoener B and Patterson SE (1981) Nitrofurantoin disposition. Clin Pharmacol Ther 29:808-816. (Pubitemid 11006731)
13. Huang L, Berry L, Ganga S, Janosky B, Chen A, Roberts J, Colletti AE, and Lin MH (2010) Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab Dispos 38:223-231.
14. Huang L, Smit JW, Meijer DK, and Vore M (2000) Mrp2 is essential for estradiol-17β(β-D-glucuronide)-induced cholestasis in rats. Hepatology 32:66-72. (Pubitemid 30432367)
15. Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, et al. (2007) SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 82:541-547. (Pubitemid 47622520)
16. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, and Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1:611-616.
17. Jani M, Szabó P, Kis E, Molnár E, Glavinas H, and Krajcsi P (2009) Kinetic characterization of sulfasalazine transport by human ATP-binding cassette G2. Biol Pharm Bull 32:497-499.
18. Kalgutkar AS, Frederick KS, Chupka J, Feng B, Kempshall S, Mireles RJ, Fenner KS, and Troutman MD (2009) N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3, 4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock-out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat. J Pharm Sci 98:4914-4927.
19. Kari FW, Weaver R, and Neville MC (1997) Active transport of nitrofurantoin across the mammary epithelium in vivo. J Pharmacol Exp Ther 280:664-668. (Pubitemid 27171326)
20. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, and Niemi M (2009) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197-203.
21. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
22. Kondo C, Suzuki H, Itoda M, Ozawa S, Sawada J, Kobayashi D, Ieiri I, Mine K, Ohtsubo K, and Sugiyama Y (2004) Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 21:1895-1903. (Pubitemid 39390103)
23. Kusuhara H, Furuie H, Inano A, Sunagawa A, Yamada S, Wu C, Fukizawa S, Morimoto N, Ieiri I, Morishita M, et al. (2012) Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol 166:1793-1803.
24. Kuteykin-Teplyakov K, Luna-Tortós C, Ambroziak K, and Löscher W (2010) Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J Pharmacol 160:1453-1463.
25. Lai Y (2009) Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion. Expert Opin Drug Metab Toxicol 5:1175-1187.
26. Lee SS, Jeong HE, Yi JM, Jung HJ, Jang JE, Kim EY, Lee SJ, and Shin JG (2007) Identification and functional assessment of BCRP polymorphisms in a Korean population. Drug Metab Dispos 35:623-632.
27. Lin X, Skolnik S, Chen X, and Wang J (2011) Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. Drug Metab Dispos 39:265-274.
28. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, and Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037. (Pubitemid 35424386)
29. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464. (Pubitemid 32695041)
30. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, and Schinkel AH (2005) The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 67:1758-1764. (Pubitemid 40594177)
31. Mizuarai S, Aozasa N, and Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced ATPase activity in multidrug transporter ABCG2. Int J Cancer 109:238-246. (Pubitemid 38240926)
32. Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, and Bates SE (2005) Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 56:161-172. (Pubitemid 40884271)
33. Robey RW, Polgar O, Deeken J, To KKW, and Bates SE (2007) Breast cancer resistant protein, in Drug Transporters (You G and Morris ME eds) pp 319-358, John Wiley, Hoboken, NJ.
34. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, and Bates SE (2009) ABCG2: a perspective. Adv Drug Deliv Rev 61:3-13.
35. Tamura A, Wakabayashi K, Onishi Y, Takeda M, Ikegami Y, Sawada S, Tsuji M, Matsuda Y, and Ishikawa T (2007) Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 98:231-239. (Pubitemid 44941876)
36. Tamura A, Watanabe M, Saito H, Nakagawa H, Kamachi T, Okura I, and Ishikawa T (2006) Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol Pharmacol 70:287-296.
37. Tchaparian EH, Houghton JS, Uyeda C, Grillo MP, and Jin L (2011) Effect of culture time on the basal expression levels of drug transporters in sandwich-cultured primary rat hepatocytes. Drug Metab Dispos 39:2387-2394.
38. Urquhart BL, Ware JA, Tirona RG, Ho RH, Leake BF, Schwarz UI, Zaher H, Palandra J, Gregor JC, Dresser GK, et al. (2008) Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics 18:439-448. (Pubitemid 351535945)
39. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
40. Yamasaki Y, Ieiri I, Kusuhara H, Sasaki T, Kimura M, Tabuchi H, Ando Y, Irie S, Ware J, Nakai Y, et al. (2008) Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther 84:95-103. (Pubitemid 351861490)
41. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, and Ware JA (2006) Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in mouse. Mol Pharm 3:55-61. (Pubitemid 43331751)
42. Zamber CP, Lamba JK, Yasuda K, Farnum J, Thummel K, Schuetz JD, and Schuetz EG (2003) Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13:19-28. (Pubitemid 36135683)
43. Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, and Higgins JW (2012) Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metab Dispos http://dx.doi.org/10.1124/dmd.112.046508.
44. Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, et al. (2006) Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 373:99-103. (Pubitemid 44292182)